EGFR and lung carcinoma: Furthermore, DRD1 modulates the expression of EGFR and PD‐L1, two molecules that are key drug targets of FDA‐approved and development‐stage therapies in lung cancer and other cancer types, so targeting DRD1 signaling may also be able to augment these therapies.